REMIGES VENTURES, INC.
REMIGES VENTURES, INC. is a Seed, Series A, Series B and Series C+ fund in the US and Japan writing $10K–$50M checks into life-sciences, healthcare-tech, drug-discovery and therapeutics.
- Stages
- Seed, Series A, Series B, Series C+
- Sectors
- life-sciences, healthcare-tech, drug-discovery, therapeutics
- Check size
- $10K–$50M
- Invests in
- US-wide, Japan
- Round role
- Leads rounds
- Actively investing
- Yes
- Founded
- 2014
- Assets under management
- $195M
Thesis
Remiges Ventures is a US-Japan cross-border venture capital firm established in 2014, focusing on early-stage investments in the life sciences and healthcare sectors, particularly in drug discovery and therapeutic development. Their strategy involves bridging the US and Japanese biotech ecosystems. The firm invests from seed to Series C+ rounds, making minority investments often alongside strategic pharma syndicates. Remiges also engages in company creation through its incubator, RDiscovery. The firm has raised two funds: Remiges BioPharma Fund II closed at $95 million in April 2021, and their RDiscovery Fund reached $100 million in May 2026. Investment sizes range from $1 million to $50 million, with a sweet spot around $1.5 million.
Common questions
Does REMIGES VENTURES, INC. invest at the Seed stage?
Yes. REMIGES VENTURES, INC. lists Seed, Series A, Series B and Series C+ among the stages it invests in.
What check size does REMIGES VENTURES, INC. write?
REMIGES VENTURES, INC. writes $10K–$50M checks.
Where does REMIGES VENTURES, INC. invest?
REMIGES VENTURES, INC. invests in the US and Japan.